Peptides for muscle gain: a primer

Peptides that raise growth hormone occupy a large corner of the performance and body-composition conversation online. Two names come up most often: ipamorelin and CJC-1295. Both affect the GH axis. Neither is approved as a medicine anywhere, and both are prohibited in competitive sport. This article explains what the research actually says about each one, what we do not yet know, and what anyone considering them should understand before making a decision.

Why the GH axis matters for muscle

Growth hormone (GH) stimulates the liver and peripheral tissues to produce insulin-like growth factor 1 (IGF-1). IGF-1 promotes protein synthesis and muscle-cell growth, and it inhibits protein breakdown. This is why raising GH is seen as a route to more muscle and less fat. The logic is broadly accepted in endocrinology, and it underlies decades of work on GH deficiency and replacement therapy.

The gap is this: raising GH in people who are not deficient does not reliably produce the same gains. The evidence base for GH supplementation in healthy, replete adults is thin and inconsistent. Most of what holds for GH-deficient patients does not transfer cleanly to people with normal GH who want more muscle. That context matters when reading the ipamorelin and CJC-1295 literature.

Ipamorelin: what the research shows

Ipamorelin is a five-amino-acid peptide (a pentapeptide) that works as a growth hormone secretagogue: it binds to the ghrelin receptor (GHS-R1a) on pituitary cells and prompts them to release GH. A 1998 study by Raun and colleagues in the European Journal of Endocrinology characterised its most notable property: selectivity^[1]. Where other GH secretagogues such as GHRP-6 and GHRP-2 also raised ACTH and cortisol when given at higher doses, ipamorelin did not produce ACTH or cortisol responses that differed significantly from baseline, even at doses 200 times its ED50 in the animal models tested.

Human pharmacokinetic data exists. A 1999 paper by Gobburu and colleagues in Pharmaceutical Research modelled ipamorelin's behaviour in healthy male volunteers across five dose levels administered as short intravenous infusions^[2]. The compound showed a short terminal half-life of around two hours. At each dose, researchers observed a single episode of GH release peaking at roughly 40 minutes and declining over the following hours. The paper characterised the dose-response relationship but was not designed to measure body composition or muscle-gain outcomes.

That last point is the most important one. Ipamorelin has no published Phase 2 or Phase 3 efficacy trial. The human data characterises how the peptide moves through the body and how much GH it releases. It does not establish that using it actually produces more muscle in healthy people over weeks or months. The step from 'raises GH' to 'builds muscle' requires its own evidence, and that evidence does not exist for ipamorelin.

CJC-1295: what the research shows

CJC-1295 is a modified 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH). Where natural GHRH has a half-life of minutes, CJC-1295 was engineered by ConjuChem in the mid-2000s to bind plasma albumin via a maleimidopropionyl linker, extending its half-life to roughly a week. Two early-phase human studies remain the strongest published data.

The first, by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism (2006), gave ascending single doses to healthy adults and then weekly or biweekly doses^[3]. After a single injection, mean plasma GH concentrations rose two to ten times over baseline for six days or more. Mean IGF-1 concentrations rose 1.5 to 3-fold and remained elevated for 9 to 11 days. After multiple doses, mean IGF-1 levels stayed above baseline for up to 28 days. No serious adverse events were reported. The dose range showing a favourable safety profile was 30 to 60 micrograms per kilogram.

The second study, by Ionescu and Frohman in the same journal (2006), looked at whether CJC-1295 preserved the natural pulsatile pattern of GH release or flattened it into a continuous low-level signal^[4]. The answer was preservation: GH pulse frequency and amplitude were maintained, while basal GH levels rose roughly 7.5-fold and mean GH rose 46%. IGF-1 rose 45%.

These are the two studies. The ConjuChem programme stalled after 2006. No Phase 2 efficacy trial measuring muscle mass, body composition, or functional outcomes was completed. CJC-1295 raises GH and IGF-1 in healthy adults, and that is the extent of what the clinical record supports.

The gap between GH elevation and muscle gain

A persistent feature of the GH secretagogue literature is that studies measuring hormones do not measure outcomes most readers care about, and studies measuring those outcomes tend to be in GH-deficient populations rather than healthy ones. The inference chain from 'CJC-1295 raises IGF-1 by 1.5 to 3-fold in healthy young adults for nine days' to 'you will gain measurable muscle over a 12-week period' involves several steps that have not been tested.

The broader GH supplementation literature in healthy older adults (using pharmaceutical recombinant HGH, not secretagogues) has generally found modest lean-mass increases alongside side-effect burdens including fluid retention, joint discomfort, and elevated glucose. The secretagogue studies have not run long enough or been large enough to characterise either the gains or the adverse-event profile at meaningful resolution.

Regulatory and safety status

Both peptides are grey-market research chemicals. Neither ipamorelin nor CJC-1295 holds a marketing authorisation from the FDA, EMA, MHRA, or any national agency covered on this site. Both are prohibited in competitive sport under the World Anti-Doping Agency (WADA) Prohibited List in the S2 category (Peptide Hormones, Growth Factors and Related Substances), which applies both in-competition and out-of-competition. For ipamorelin specifically, the US FDA's Pharmacy Compounding Advisory Committee declined to recommend it for inclusion on the 503A bulks list, meaning compound pharmacies in the US cannot legally dispense it. Full regulatory detail for each jurisdiction is on the ipamorelin regulation page and the CJC-1295 regulation page.

What is sold online as ipamorelin or CJC-1295 is typically labelled 'for research use only.' That label does not reflect the way the products are marketed or used in practice, and it does not confer legal permission for human use. Independent purity testing of grey-market peptides frequently finds incorrect concentrations, contamination, and mislabelling.

What we do not yet know

The honest short list: whether either peptide produces meaningful muscle gain in healthy adults over a realistic timeframe; what the adverse-event profile looks like over months of use; whether the GH and IGF-1 elevations documented in the early-phase trials translate into clinical outcomes; and whether long-term GH axis stimulation carries risks that short trials cannot detect. These questions are not rhetorical. They are genuinely unanswered.

If you are considering either peptide

That conversation belongs with a clinician who knows your medical history, your baseline hormone levels, and your jurisdiction's legal position. The per-peptide pages on this site cover the mechanism, evidence, and regulatory status in more depth: ipamorelin and CJC-1295. For guidance on what baseline and follow-up blood markers matter when using peptides, see the overview on blood tests before and after a peptide course.